Back to top
more

Viatris (VTRS)

(Real Time Quote from BATS)

$11.13 USD

11.13
2,255,568

+0.24 (2.20%)

Updated Jul 11, 2024 01:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Viatris (VTRS) Up 13.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Viatris' (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

Viatris (VTRS) beats on Q1 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.

Viatris (VTRS) Q1 Earnings Beat Estimates

by Zacks Equity Research

Viatris (VTRS) delivered earnings and revenue surprises of 14.81% and 0.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Theravance's (TBPH) Q1 Earnings and Sales Miss Estimates

by Zacks Equity Research

Theravance (TBPH) reports wider-than-expected loss for the first quarter of 2022. Revenues decline year over year.

Alignment Healthcare (ALHC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 4.17% and 3.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Viatris' (VTRS) Q1 earnings might have been adversely impacted by competition in the complex generics business.

Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Viatris (VTRS) closed the most recent trading day at $10.21, moving -1.16% from the previous trading session.

Earnings Preview: Viatris (VTRS) Q1 Earnings Expected to Decline

by Zacks Equity Research

Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Viatris (VTRS) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Viatris (VTRS) closed the most recent trading day at $10.39, moving +1.07% from the previous trading session.

Viatris (VTRS) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Viatris (VTRS) closed the most recent trading day at $10.92, moving +1.96% from the previous trading session.

Viatris (VTRS) Stock Moves -0.28%: What You Should Know

by Zacks Equity Research

Viatris (VTRS) closed the most recent trading day at $10.67, moving -0.28% from the previous trading session.

Viatris (VTRS) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Viatris (VTRS) closed the most recent trading day at $10.67, moving -1.66% from the previous trading session.

Theravance's (TBPH) Hypotension Study Misses Primary Goal

by Zacks Equity Research

Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic nOH fails to meet its goal. The study benefitted patients with a rare neurodegenerative disorder.

    Viatris (VTRS) Dips More Than Broader Markets: What You Should Know

    by Zacks Equity Research

    Viatris (VTRS) closed the most recent trading day at $10.99, moving -1.7% from the previous trading session.

    Viatris (VTRS) Up 10.2% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Viatris (VTRS) Gains As Market Dips: What You Should Know

    by Zacks Equity Research

    In the latest trading session, Viatris (VTRS) closed at $10.88, marking a +0.28% move from the previous day.

    Viatris (VTRS) Gains As Market Dips: What You Should Know

    by Zacks Equity Research

    In the latest trading session, Viatris (VTRS) closed at $10.77, marking a +1.03% move from the previous day.

    Viatris (VTRS) Gains But Lags Market: What You Should Know

    by Zacks Equity Research

    Viatris (VTRS) closed the most recent trading day at $9.96, moving +1.53% from the previous trading session.

    Why is Viatris (VTRS) Stock Down 25% in the Year So Far?

    by Zacks Equity Research

    Viatris (VTRS) stock drops 25% in the year so far as investors do not seem to be impressed by the impending sale of its biosimilar business.

    Company News for Mar 1, 2022

    by Zacks Equity Research

    Companies In The News Are: JLL, TGNA, XRAY, VTRS.

    Viatris' (VTRS) Q4 Earnings Miss, Biocon Biologics Deal Inked

    by Zacks Equity Research

    Viatris (VTRS) misses on Q4 earnings but surpasses sales estimates. The company announces a combination of its biosimilars portfolio with Biocon Biologics.

    Viatris (VTRS) Q4 Earnings Miss Estimates

    by Zacks Equity Research

    Viatris (VTRS) delivered earnings and revenue surprises of -2.44% and 0.71%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Why Viatris (VTRS) Might Surprise This Earnings Season

    by Zacks Equity Research

    Viatris (VTRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Theravance's (TBPH) Q4 Earnings and Sales Miss Estimates

    by Zacks Equity Research

    Theravance (TBPH) reports wider-than-expected loss for the fourth quarter of 2021. Revenues decline year over year.

    Viatris (VTRS) Stock Moves -1.58%: What You Should Know

    by Zacks Equity Research

    Viatris (VTRS) closed the most recent trading day at $14.32, moving -1.58% from the previous trading session.